Malaria Vaccines
CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology
Published in Healthcare Mergers, Acquisitions and Ventures Week, June 13th, 2009
CEL-SCI Corporation (NYSE AMEX: CVM) announced that it is developing an immune-based treatment for the "swine flu and related H1N1" flu viruses, utilizing its proprietary L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology. The Company plans to utilize the expertise and knowledge it has gained from developing protective and therapeutic vaccines utilizing L.E.A.P.S. to develop a therapeutic treatment based upon the technology for people infected with the swine and H1N1 flu viruses. CEL-SCI has already commenced pre-clinical testing.
Previously, CEL-SCI announced that its CEL-1000 peptide, which is derived from the L.E.A.P.S. technology, showed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- 4SC AG
4SC presents Phase I data on its histone deacetylase HDAC inhibitor 4SC-201 at ASCO - A. Schulman, Inc.
A. Schulman Appoints Kim L. Whiteman to Head Global Human Resources Team - A. Schulman, Inc.
A. Schulman Expands Sunprene Elastomers Line for Industrial, Specialty Wire & Cable, and Heavy Truck Markets - ABI Research
Wireless Communications Sector Will Reap Huge Benefit from $6.8 Billion Stimulus Bill Funding, Says ABI Research - Abraxis BioScience, Inc.
Marty J. Duvall Joins Abraxis BioScience as Senior Vice President, Global Marketing and International Commercial Operations - Acacia Research Corporation
Acacia Subsidiary Enters into License Agreement with KYRSAGIH BROS. LIMITED LIABILITY COMPANY - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
